News in brief - December 2014 (updated)

Other new launches, licence changes and updates relevant to general practice.

Epimax can be used as a leave-on emollient and as a soap substitute.
Epimax can be used as a leave-on emollient and as a soap substitute.
  • Actavis has launched Sastravi (levodopa/carbidopa/entacapone) for the treatment of Parkinson's disease and end-of-dose motor fluctuations not stabilised with levodopa/dopa decarboxylase inhibitor.
  • Noxafil (posaconazole) is now available as a 300mg concentrate for solution for infusion. The antifungal from MSD is also available as tablets and an oral suspension.
  • Sanofi has discontinued Piportil Depot (pipotiazine palmitate) owing to a global shortage of the active ingredient. Supplies of the injection are expected to be exhausted by the end of March 2015.
  • Epimax is a new formulation of aqueous cream that does not contain the potential sensitiser sodium lauryl sulfate.
  • The Calcichew range now includes Calcichew-D3 1g/800iu Once Daily, a high-dose calcium/vitamin D chewable tablet containing 2.5g calcium carbonate (equivalent to 1g calcium) and 800iu vitamin D3 (colecalciferol).
  • The new haemophilia A treatment Nuwiq (simoctocog alfa) is a recombinant human coagulation factor VIII produced in a human cell-line.

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in